In addition, the specific IL6ST inhibitor bazedoxifene (BZA) has long been approved by the US FDA as a selective modulator of estrogen receptors to treat osteoporosis (50), suggesting the promise of IL6ST inhibitors as drugs. The gene discussed is ESR1; the disease is osteoporosis.